SCHEMBL3144077

SCHEMBL3144077

COc1ccc2c3c(oc2c1)CCCC3

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.52
TP53 P04637 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
KDM4E B2RXH2 7/20 0.51
ALDH1A1 P00352 6/20 0.51
HPGD P15428 4/20 0.51
HSD17B10 Q99714 4/20 0.51
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
CYP3A4 P08684 2/20 0.50
USP2 O75604 1/20 0.50
ALOX15 P16050 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
STS P08842 2/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
POLB P06746 1/20 0.49
STAT1 P42224 1/20 0.49
HDAC1 Q13547 3/20 0.48
TSHR P16473 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1101935 0.87 MAPT (0.62) MAPTTP53KDM4EALDH1A1HPGD
SCHEMBL25896205 0.84 HTR6 (0.58) MAPTTDP1KDM4EALDH1A1HPGD
SCHEMBL31355018 0.84 HTR6 (0.58) MAPTTDP1KDM4EALDH1A1HPGD
SCHEMBL31354906 0.83 HDAC1 (0.53) HDAC1DRD2DRD4
SCHEMBL25895980 0.83 HDAC1 (0.53) HDAC1DRD2DRD4
SCHEMBL25897440 0.83 HTR6 (0.57) MAPTTDP1KDM4EALDH1A1HPGD
SCHEMBL31355003 0.83 HTR6 (0.57) MAPTTDP1KDM4EALDH1A1HPGD
SCHEMBL25896131 0.82 HTR6 (0.54) MAPTTDP1KDM4EALDH1A1HPGD
SCHEMBL31354968 0.82 HTR6 (0.54) MAPTTDP1KDM4EALDH1A1HPGD
SCHEMBL31354909 0.81 HDAC1 (0.55) HDAC1DRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2137193-B1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI SA (FR) 2017-08-09 EP disclosed
US-8642603-B2 Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof SANOFI (FR) 2014-02-04 US disclosed
US-20100075994-A1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI-AVENTIS (FR) 2010-03-25 US disclosed
EP-2137193-A2 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF Sanofi-Aventis (FR) 2009-12-30 EP disclosed
WO-2008112483-A2 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI-AVENTIS (FR) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075994-A1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF GRM2, GRM1, GRIN2C MAPT 1382/4885TP53 4885/4885TDP1 1955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.